| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/22/1999 | WO1999036076A1 Composition containing propargylamine for enhancing cancer therapy |
| 07/22/1999 | WO1999036075A1 Oral oil sorbing composition |
| 07/22/1999 | WO1999036064A2 Methods of treating tardive dyskinesia and other movement disorders |
| 07/22/1999 | WO1999036060A1 Oral liquid compositions |
| 07/22/1999 | WO1999017712A3 Tightening and/or reducing the size of body parts containing fat cells |
| 07/22/1999 | WO1999016407A3 Method and system for pain management |
| 07/22/1999 | WO1999005291A3 Aggrecan degrading metallo proteases |
| 07/22/1999 | CA2318693A1 Composition containing propargylamine for enhancing cancer therapy |
| 07/22/1999 | CA2318661A1 Transglutaminase linkage of agents to tissue |
| 07/22/1999 | CA2318525A1 Methods of using human receptor protein 4-1bb |
| 07/22/1999 | CA2318236A1 Oral oil sorbing composition |
| 07/22/1999 | CA2318037A1 Methods of neuroendocrine regulation of affective disorders |
| 07/22/1999 | CA2315299A1 Fatty acid synthase mrna binding protein |
| 07/21/1999 | EP0930076A1 Medicinal compositions |
| 07/21/1999 | EP0930075A1 Methods for preventing, inhibiting or treating graft rejection reactions in graft-versus-host disease (gvhd) and organ transplantation |
| 07/21/1999 | EP0930069A2 Compositions for the reduction of scarring |
| 07/21/1999 | EP0930067A2 Mmp inhibitors for the treatment of ocular angiogenesis |
| 07/21/1999 | EP0929688A1 Sustained delivery device and methods of making and using the same |
| 07/21/1999 | EP0929675A2 Nucleotide and protein sequence of mammastatin and methods of use |
| 07/21/1999 | EP0929674A2 HUMAN Bad POLYPEPTIDES, ENCODING NUCLEIC ACIDS AND METHODS OF USE |
| 07/21/1999 | EP0929673A2 Tumor proteins |
| 07/21/1999 | EP0929672A1 Human gtp binding protein gamma-3 |
| 07/21/1999 | EP0929311A1 INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS |
| 07/21/1999 | EP0929306A1 Method of inhibiting smooth muscle cell proliferation |
| 07/21/1999 | EP0929303A2 Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agent |
| 07/21/1999 | EP0929300A2 Cyanidin compositions and therapeutic and diagnostic uses therefor |
| 07/21/1999 | EP0374207B1 Drug for treating cancer, aids and viral diseases |
| 07/21/1999 | CN1223690A Antiangiogenic peptides derived from plasminogen, its coded polynucleotide and method of inhibiting vascularization |
| 07/21/1999 | CN1223581A Anti-vaginitis composition for topical use comprising one or more anti-vaginitis medicaments and one or more local anaesthetics |
| 07/21/1999 | CN1223546A Antimicrobial treatment for herpes simplex virus and other infectious diseases |
| 07/20/1999 | US5925669 Antitumor agents |
| 07/20/1999 | US5925642 Pyridopyrimidines |
| 07/20/1999 | US5925634 Use of ibogaine for treating neuropathic pain |
| 07/20/1999 | US5925629 Sexual dysfunction |
| 07/20/1999 | US5925627 Use of NK-1 receptor antagonists for treating movement disorders |
| 07/20/1999 | US5925626 Hyaluronic acid fractions having pharmaceutical activity, and pharmaceutical compositions containing the same |
| 07/20/1999 | US5925616 Synergistic mixtures |
| 07/20/1999 | US5925568 It is also useful to be able to harvest haematopoietic cells prior to chemotherapy or radiotherapy, thus protecting them from the effects of this therapy; after therapy, the cells can be returned to the patient. |
| 07/20/1999 | US5925567 Selective expansion of target cell populations |
| 07/20/1999 | US5925557 This invention relates generally to the field of protein kinases, oncogenes and oncoproteins and, specifically, to a protein kinase which phosphorylates and potentiates the activity of c-fos. |
| 07/20/1999 | US5925539 Human pelota homolog |
| 07/20/1999 | US5925536 Receptor-type phosphotyrosine phosphatase-β |
| 07/20/1999 | US5925521 Human serine carboxypeptidase |
| 07/20/1999 | US5925333 Screening for compounds that alter the binding by scavengers |
| 07/15/1999 | WO1999035292A1 Compositions and methods for treating cells having double minute dna |
| 07/15/1999 | WO1999035277A2 Recombinant, active caspases and uses thereof |
| 07/15/1999 | WO1999035266A2 Human urotensin ii |
| 07/15/1999 | WO1999035259A1 Identification of lysolipid receptors involved in inflammatory response |
| 07/15/1999 | WO1999035246A1 Novel steroid-activated nuclear receptors and uses therefor |
| 07/15/1999 | WO1999035243A2 Extension of cellular lifespan, methods and reagents |
| 07/15/1999 | WO1999034828A1 A transdermally administered pharmaceutical composition containing astringents |
| 07/15/1999 | WO1999034822A1 Formulations for amylin agonist peptides |
| 07/15/1999 | WO1999034817A1 Agent for treating allergic or hypersensitivity condition |
| 07/15/1999 | WO1999034816A1 Method for administering monomeric insulin analogs |
| 07/15/1999 | WO1999034815A1 Method for administering aspb28-human insulin |
| 07/15/1999 | WO1999034809A1 Solid iodophor preparations and process for producing the same |
| 07/15/1999 | WO1999034805A1 Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection |
| 07/15/1999 | WO1999034804A1 A2a adenosine receptor agonists |
| 07/15/1999 | WO1999034796A1 Synergistic antitumor composition containing a naphthalensulphonic acid derivative |
| 07/15/1999 | WO1999034792A1 Use of mek1 inhibitors as protective agents against damage due to ischemia |
| 07/15/1999 | WO1999034783A1 USE OF PPAR-η ACTIVATORS IN DERMATOLOGY |
| 07/15/1999 | WO1999034776A1 Nasal drop compositions |
| 07/15/1999 | WO1999025857A3 Transgenic models of inflammatory disease |
| 07/15/1999 | WO1999025734A3 Th2 CELL DEPLETION; COMPOSITIONS; METHODS |
| 07/15/1999 | WO1999021582A3 Application of tnf antagonists as medicaments for treating septic diseases |
| 07/15/1999 | WO1999013095A9 Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses |
| 07/15/1999 | WO1998053066A9 Smad2 phosphorylation and interaction with smad4 |
| 07/15/1999 | CA2365742A1 Formulations for amylin agonist peptides |
| 07/15/1999 | CA2324972A1 Identification of lysolipid receptors involved in inflammatory response |
| 07/15/1999 | CA2318380A1 Compositions and methods for treating cells having double minute dna |
| 07/15/1999 | CA2318369A1 Recombinant, active caspases and uses thereof |
| 07/15/1999 | CA2317739A1 Method for administering aspb28-human insulin |
| 07/15/1999 | CA2317733A1 Method for administering monomeric insulin analogs |
| 07/15/1999 | CA2317587A1 Solid iodophor preparations and process for producing the same |
| 07/15/1999 | CA2317093A1 A2a adenosine receptor agonists |
| 07/15/1999 | CA2315265A1 Extension of cellular lifespan, methods and reagents |
| 07/15/1999 | CA2296999A1 Activated t-cells and their uses |
| 07/15/1999 | CA2245909A1 Novel compounds |
| 07/14/1999 | EP0928337A1 A human protein tyrosine kinase |
| 07/14/1999 | EP0928336A1 Chaperone fragments |
| 07/14/1999 | EP0928328A1 Methods for culturing cells |
| 07/14/1999 | EP0928306A1 Antiviral linear polymers |
| 07/14/1999 | EP0928200A2 Therapeutic combinations of rar antagonists and rxr agonists |
| 07/14/1999 | EP0928194A1 Compositions and methods for administering integrin receptor antagonists |
| 07/14/1999 | EP0928192A1 Antimycotic gel with high active substance release |
| 07/14/1999 | EP0553198B1 Regulation of immunoglobulin production by interleukin-9 |
| 07/14/1999 | CN1222917A Novel protein and process for producing the same |
| 07/14/1999 | CN1222850A Therapeutic treatment for VEGF related occular diseases |
| 07/13/1999 | US5922857 Methods and compositions for controlling translation of HCV proteins |
| 07/13/1999 | US5922853 Human pelota homolog |
| 07/13/1999 | US5922773 Treatment with n-methyl-d-aspartate antagonist for vision defects |
| 07/13/1999 | US5922761 Methods for in vivo reduction of iron levels and compositions useful therefor |
| 07/13/1999 | US5922746 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| 07/13/1999 | US5922705 Rapid narcotic detoxification |
| 07/13/1999 | US5922687 Placing the nucleic acid in an extracellular environment of the cell, defining an enclosure comprising the cell and the extracellular environmenat, establishing an incubation pressure within the enclosure; useful for gene therapy |
| 07/13/1999 | US5922674 Inhibiting endothelial cell proliferation in a subject treated by with platinum coordination complex chemotherapeutic agent by simultaneous administration of erythropoietin |
| 07/13/1999 | US5922595 Cyclic GMP phosphodiesterase |
| 07/13/1999 | US5922566 Polynucleotide |
| 07/13/1999 | US5922546 Human disintegrin metalloprotease KUZ gene |
| 07/13/1999 | US5922350 Dehydration in presence of sugars present at a protectiveconcentration on both inside and outside surfaces; liposomeshave ion concentration gradient capable of generatingtransmember potential to load charged material |